Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020112109 - KLRG1 SIGNALING THERAPY

Publication Number WO/2020/112109
Publication Date 04.06.2020
International Application No. PCT/US2018/062971
International Filing Date 29.11.2018
IPC
A61K 39/395 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
CPC
A61K 2039/505
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
505comprising antibodies
A61K 2039/507
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
505comprising antibodies
507Comprising a combination of two or more separate antibodies
A61K 2039/544
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
54characterised by the route of administration
541Mucosal route
544to the airways
A61K 2039/545
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
545characterised by the dose, timing or administration schedule
A61K 38/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies
Applicants
  • THE BRIGHAM AND WOMEN'S HOSPITAL [US]/[US]
Inventors
  • GREENBERG, Steven
  • GULLA, Stefano, Vincenzo
  • THOMPSON, Kenneth, Evan
Agents
  • PHEIFFER, Rory, P.
  • DECLOUX, Amy, M.
  • FILANDRIANOS, Emmanuel, D.
  • CAHILL, Ronald, E.
  • GERETY, Todd
Priority Data
16/203,58728.11.2018US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) KLRG1 SIGNALING THERAPY
(FR) TRAITEMENT DE SIGNALISATION PAR KLRG1
Abstract
(EN)
A method of treating a subject can include administering to a subject in need thereof an effective amount of a killer cell lectin-like receptor Gl (KLRGl)/ligand binding agent, thereby disrupting KLRG1 signaling and activating CD8+ cytotoxic T and/or NK cells. A method of treating cancer can include administering to a subject in need thereof an effective amount of a killer cell lectin-like receptor Gl (KLRGl)/ligand binding agent. The methods can treat various cancers, for example melanoma, lung cancer, pancreatic cancer, glioma, breast cancer, ovarian cancer, metastatic breast cancer, and colon cancer.
(FR)
L'invention concerne une méthode de traitement d'un sujet pouvant comprendre l'administration à un sujet qui en a besoin d'une quantité efficace d'un agent de liaison au récepteur de cellules tueuses de type lectine GI (KLRGI)/ligand, pour interrompre ainsi la signalisation par KLRG1 et activer les lymphocytes T et/ou les cellules NK cytotoxiques CD8+. L'invention concerne également une méthode de traitement du cancer pouvant comprendre l'administration à un sujet qui en a besoin d'une quantité efficace d'un agent de liaison au récepteur de cellules tueuses de type lectine GI (KLRGI)/ligand. Les méthodes de l'invention permettent de traiter divers cancers, par exemple le mélanome, le cancer du poumon, le cancer du pancréas, le gliome, le cancer du sein, le cancer de l'ovaire, le cancer du sein métastatique et le cancer du côlon.
Also published as
Latest bibliographic data on file with the International Bureau